Literature DB >> 18804344

Ketamine successfully terminates malignant status epilepticus.

Harald Prüss1, Martin Holtkamp.   

Abstract

A 22-year-old woman with mitochondriopathy and pre-existing epilepsy developed status epilepticus (SE) not responding to benzodiazepines, phenytoin, thiopental, and propofol. SE was terminated within days after supplemental administration of continuous ketamine infusion to midazolam. The case suggests strong anticonvulsant properties of ketamine even after failure of GABAergic anesthetics, likely due to increased NMDA receptor expression with ongoing seizure activity. Thus, ketamine should be incorporated into therapeutic regimens for difficult-to-treat SE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18804344     DOI: 10.1016/j.eplepsyres.2008.08.005

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  26 in total

Review 1.  Management of refractory status epilepticus in adults: still more questions than answers.

Authors:  Andrea O Rossetti; Daniel H Lowenstein
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

2.  Treatment of refractory status epilepticus in childhood.

Authors:  John M Schreiber; William D Gaillard
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

Review 3.  Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.

Authors:  Annamaria Vezzani; Raymond Dingledine; Andrea O Rossetti
Journal:  Expert Rev Neurother       Date:  2015       Impact factor: 4.618

4.  Ketamine for Refractory Status Epilepticus: A Systematic Review.

Authors:  Anna Rosati; Salvatore De Masi; Renzo Guerrini
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

5.  Sea food consumption for improving cardiac and cerebral manifestations of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes.

Authors:  Fulvio A Scorza; Josef Finsterer
Journal:  Ann Transl Med       Date:  2017-09

6.  Anti-N-methyl-D-aspartate receptor encephalitis with favorable outcome despite prolonged status epilepticus.

Authors:  Xavier Finné Lenoir; Christian Sindic; Vincent van Pesch; Souraya El Sankari; Marianne de Tourtchaninoff; Roger Denays; Philippe Hantson
Journal:  Neurocrit Care       Date:  2013-02       Impact factor: 3.210

7.  Generalized seizure activity in an adult rhesus macaque (Macaca mulatta) during ketamine anesthesia and urodynamic studies.

Authors:  Kari L Christe; Una J Lee; Marie-Josee Lemoy; Leif A Havton
Journal:  Comp Med       Date:  2013-10       Impact factor: 0.982

8.  Ketamine for medically refractory status epilepticus after elective aneurysm clipping.

Authors:  F A Zeiler; A M Kaufmann; L M Gillman; M West; J Silvaggio
Journal:  Neurocrit Care       Date:  2013-08       Impact factor: 3.210

9.  Ketamine to treat super-refractory status epilepticus.

Authors:  Ayham Alkhachroum; Caroline A Der-Nigoghossian; Elizabeth Mathews; Nina Massad; Riva Letchinger; Kevin Doyle; Wei-Ting Chiu; Julie Kromm; Clio Rubinos; Angela Velazquez; David Roh; Sachin Agarwal; Soojin Park; E Sander Connolly; Jan Claassen
Journal:  Neurology       Date:  2020-09-01       Impact factor: 9.910

Review 10.  NMDA antagonists for refractory seizures.

Authors:  F A Zeiler; J Teitelbaum; L M Gillman; M West
Journal:  Neurocrit Care       Date:  2014-06       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.